41 results on '"P Paubel"'
Search Results
2. HPR12 Assessment of the French National Experimentation for Incentivising Hospital Prescriptions of Adalimumab Biosimilars Delivered in Retail Pharmacies
3. HPR154 Appropriate Use of Anti-PD(L)1 in Paris Public Hospitals (AP-HP): Are the Prescriptions in Compliance with Reimbursed Indications?
4. EE352 New Reimbursement Policy on Costly Treatments for Rehabilitation Care in France: Estimated Impact in a University Hospital
5. HPR26 Anti-PD(L)1: Does the Cost of Treatment Have an Impact on the Therapeutic Decision-Making?
6. EE616 Management of Chronic Lymphocytic Leukemia: What Impact on Consumption and Expenditure?
7. HPR14 Identifying the Key Drivers of Biosimilar Uptake in Paris University Hospitals Using a Principal Component Analysis
8. HTA147 Advanced Therapy Medicinal Products (ATMPS) Market Access Challenges in France
9. HPR208 Analysis of Substitution Procurement Agreements and Financial Impact in a University Hospital Structure
10. POSA217 The Reform of the French Compassionate Use Program : The State and Perspective Before the Change
11. POSC224 Drug Supply Chain Disruption: Retrospective Analysis of Substitution Procurement Agreements in a University Hospital Structure
12. PRO45 Emicizumab: Extension of the Target Population and Change of the Dispensation Channel, What Financial IMPACT for the Public Hospitals of Paris?
13. PBI63 IMPACT OF TOCILIZUMAB SUBCUTANEOUS INJECTION COMMERCIALIZATION ON PRACTICES IN THE PUBLIC HOSPITALS OF PARIS
14. A medico-economic study of trabectedin compared with end-stage treatment in soft tissue sarcomas
15. PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARIS
16. Hospital Reimbursement Price Cap for Cancer Drugs: The French Experience in Controlling Hospital Drug Expenditures
17. PMD114 - ASSESSING AND MODELING ORGANIZATIONAL IMPACT OF TILMANOCEPT IN PERFORMING SENTINEL LYMPH NODE BIOPSY IN FRANCE
18. PRM276 - METHODOLOGICAL ISSUES OF DRUG PRICE COMPARISON STUDIES: WHAT IMPROVEMENT IN QUALITY?
19. PIN86 - COST SAVINGS TO BE EXPECTED FROM THE INTRODUCTION OF NEW ANTI-HIV GENERICS IN UNIVERSITY PUBLIC HOSPITALS OF PARIS
20. PCN291 - MARKET ACCESS FOR ONCO-HEMATOLOGY MEDICINES : VALUE OF SINGLE ARM STUDIES - ANALYSIS OF FRENCH HTA OPINIONS
21. PHP183 - PRICE DIFFERENCE OF MEDICINES DISPENSED IN COMMUNITY PHARMACIES AND IN THE HOSPITAL SECTOR : AN ANALYSIS ON THE MEDICINES FINANCED ON THE BASIS OF HOSPITAL SERVICE TARIFFS
22. PCP68 - MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCE
23. PSY45 - BUDGET IMPACT ANALYSIS OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE
24. Anti-PD1 Drugs: Are The Reimbursed Indications Of The Marketing Authorization Respected?
25. Reimbursement of Vedolizumab According to the Indications: what are the Impacts in the 37 Public Hospitals of Paris?
26. Economic Impact of French Public Regulations on Ferric Carboxymaltose in 39 Paris Public Hospitals Over the 2013-2016 Period
27. Budget Impact Analysis of Implementing Tenders Between The Branded Infliximab And Its Biosimilars In The Public Hospitals of Paris
28. Defibrotide in Veno-Occlusive Disease in Public Hospitals of Paris: Funding Issues and Perspectives
29. Economic Impact of The End of The Market Exclusivity for Orphan Drugs
30. Does Hospital At Home Need A New Funding For Oral Anti-Cancer Drugs ?
31. Biosimilar Infliximab In The 37 Public Hospitals Of Paris: Meeting The Challenge Of Substitution
32. Comparative Analysis Of Medicine's Purchassing Prices Of 'Additional List'(Aphp Versus French Hospitals Formely Under Overall Allocation)
33. Cost-Effectiveness Analyses In France, England And Canada: Comparative Analysis Of Structural Choices, Results And Perspectives
34. Economic Burden of Anti-Methicillin-Resistant Staphylococcus Aureus (Mrsa) Therapy in Public Hospitals of Paris (Ap-Hp) and Adequacy with the Defined Daily Doses
35. The Shift From A Compassionate Drug Use To The Common Market–Access Process: An Inflationary No Man’s Land?
36. Economic Consequences Of The Choices In Injectable Anticoagulants In France
37. Biosimilar Infliximab: Feedback After A Nine Months Experience Of Their Use In The 37 Public Hospitals Of Paris
38. Increase Hospital Physicians’ Awareness of Expenditure Generated by Their Prescription in the Ambulatory Sector: Learning from the Experience of the 37 Public Hospitals of Paris in Diabetology
39. War Rages Between Infliximab Biosimilars and Their Originator
40. Funding Expensive Drugs In Hospitals: Where Is France Going?
41. PHP9 Temporary Use Authorizations: The Economic and Clinical Future of Drugs Used in the French Compassionate Program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.